Survival Trends in Patients with Tracheal Carcinoma from 1973 to 2011

Agrawal, Surbhi; Dodhia, Chetan; Guzmán, Carlos; Jackson, Christopher M.; Celie, Karel-Bart; Hellenthal, Nicholas J.; Monie, Daphne; Monzon, Jose R.; Kaufman, Theodor

doi:10.1016/j.jamcollsurg.2016.08.474

Cited by 4 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They represent 0.1-0.4% of all newly diagnosed cancers (1,2). The two main histological subtypes of tracheal cancer are adenoid cystic carcinoma (ACC) and squamous cell carcinoma (SCC) (2,3).…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics, surgical treatments, prognosis, and prognostic factors of primary tracheal cancer patients: 20-year data of the National Cancer Center, China

Li¹,

Tan²,

Wang³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: Tracheal cancer is a rare malignancy of which previous reports are mostly case reports or small series. Herein, we sought to evaluate the clinical characteristics, surgical treatments, and prognosis of surgically treated primary tracheal cancer patients.Methods: Patients with primary tracheal cancer who had received surgery in our center between January 2000 and December 2020 were enrolled. Clinical and surgical features were collected by retrospective review of medical records and follow-up was done by telephone interview. The statistical tests were two-sided.Results: A total of 128 patients were included in the study, 49.2% of whom were male, and the average age was 49.4±13.6 years. The most common histological subtype was adenoid cystic carcinoma (ACC; 78/128, 60.9%) followed by squamous cell carcinoma (SCC; 24/128, 18.8%). The percentage of tumors located in the cervical trachea, thoracic trachea, and carina were 50%, 41.4%, and 8.6%, respectively. Among those analyzed, 32.0% of the primary tumors had invaded adjacent organs (E2 disease) and 7.8% of patients had lymph node involvement. Tracheal resection plus reconstruction (with or without thyroidectomy) was the predominant surgical procedure, followed by carinal resection with neocarina. Radical resection (R0) was performed on 61.7% of patients and 63 (49.2%) patients received adjuvant therapy. Compared to ACC, SCC patients had significantly higher risk of tumor of the carina, nodal metastasis, and complications. The 5-year overall survival (OS) for the entire cohort was 84.5% and factors associated with poor prognosis included carinal tumor [hazard ratio (HR) =10.206; P<0.001], E2 disease (HR =8.870; P=0.001), lymph node metastasis (HR =15.197; P<0.001), and postoperative complications (HR =12.497; P=0.001). Conclusions: The two major subtypes of tracheal cancer are ACC and SCC. Tumor location, extension, lymph node metastasis and complication are survival related factors for surgically treated patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical characteristics, surgical treatments, prognosis, and prognostic factors of primary tracheal cancer patients: 20-year data of the National Cancer Center, China

Li¹,

Tan²,

Wang³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…Surgical methods include local resection, radical surgery, and electrocautery ablation (9,11). Adenocarcinoma and primary tracheal non-Hodgkin's lymphoma are more sensitive to radiotherapy (12)(13)(14)(15).…”

Section: Discussionmentioning

confidence: 99%

The Prognostic Value of ¹⁸F-Fluorodeoxyglucose PET/CT in the Initial Assessment of Primary Tracheal Malignant Tumor: A Retrospective Study

et al. 2021

View full text Add to dashboard Cite

Objective: To investigate the potential value of 18 F-fluorodeoxyglucose (FDG) PET/CT in predicting the survival of patients with primary tracheal malignant tumors. Materials and Methods: An analysis of FDG PET/CT findings in 37 primary tracheal malignant tumor patients with a median follow-up period of 43.2 months (range, 10.8-143.2 months) was performed. Cox proportional hazards regression analyses were used to assess the associations between quantitative 18 F-FDG PET/CT parameters, other clinic-pathological factors, and overall survival (OS). A risk prognosis model was established according to the independent prognostic factors identified on multivariate analysis. A survival curve determined by the Kaplan-Meier method was used to assess whether the prognosis prediction model could effectively stratify patients with different risks factors. Results: The median survival time of the 37 patients with tracheal tumors was 38.0 months, with a 95% confidence interval of 10.8 to 65.2 months. The 3-year, 5-year and 10-year survival rate were 54.1%, 43.2%, and 16.2%, respectively. The metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value, age, pathological type, extension categories, and lymph node stage were included in multivariate analyses. Multivariate analysis showed MTV (p = 0.011), TLG (p = 0.020), pathological type (p = 0.037), and extension categories (p = 0.038) were independent prognostic factors for OS. Additionally, assessment of the survival curve using the Kaplan-Meier method showed that our prognosis prediction model can effectively stratify patients with different risks factors (p < 0.001). Conclusion: This study shows that 18 F-FDG PET/CT can predict the survival of patients with primary tracheal malignant tumors. Patients with an MTV > 5.19, a TLG > 16.94 on PET/CT scans, squamous cell carcinoma, and non-E1 were more likely to have a reduced OS.

show abstract

“…Interestingly, 26% of patients in our cohort underwent definitive CRT, making it the most common form of treatment. The variation in treatment rates across studies may be due to changing trends over time, with many earlier studies consisting of data from several decades ago and due to systemic therapy not being previously recorded in national databases …”

Section: Discussionmentioning

confidence: 99%

“…Analysis of an English national registry also demonstrated improved survival for those who underwent curative resection compared to survival overall (60.8% vs. 19.5%) . Lastly, an analysis of the Surveillance, Epidemiology, and End Results (SEER) database in 2017 by Agrawal et al demonstrated improved OS and cancer‐specific survival among patients who underwent surgery alone or surgery plus RT compared to no treatment or RT alone . Arguments against these findings state that differences observed between surgical candidates and nonsurgical candidates are most likely because patients with resectable tumors present with more localized malignancy, with smaller tumors, without distant metastasis, and with younger age and fewer health comorbidities.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology and treatment trends for primary tracheal squamous cell carcinoma

et al. 2019

View full text Add to dashboard Cite

Objective Management of tracheal squamous cell carcinoma (TSCC) has been complicated by the lack of prognostic data and staging. We describe the epidemiology of TSCC and current treatment approaches. Methods Five hundred thirty‐two adult patients with primary TSCC from 2004 to 2012 in the National Cancer Database were identified. Demographic, clinical factors, and 5‐year overall survival were analyzed. Staging was classified as localized, regional extension, and distant spread. Treatment modality was defined as “no treatment (NT),” “limited surgery (LS),” “curative surgery (CS),” “LS with any adjuvant therapy (AT) (LS+AT),” “CS with AT (CS+AT),” “radiation therapy (RT),” or “chemoradiation (CRT).” Results Overall survival was 25%. Majority of cases were males, white, and occurred in sixth/seventh decades. Twenty‐six percent of cases received CRT, 20% underwent LS+AT or CS+AT, 20% underwent LS or CS only, and 17% underwent RT alone. On multivariate analysis, CS (HR 0.42, 95% CI: 0.26–0.69), CS+AT (HR 0.44, 95% CI: 0.36–0.77), CRT (HR 0.48, 95% CI: 0.35–0.67), and RT (HR, 0.66 95% CI: 0.46–0.94) were associated with decreased likelihood of death compared to NT. Elderly patients and those with poor performance status had worse outcomes even on multivariate analysis. Conclusions TSCC is increasingly treated with surgery and systemic therapy in addition to RT, with improved survival outcomes. CS, CS+AT, CRT, or RT provided improved survival advantage in patients with variable levels of improvement based on the extent of the disease. Prospective trials would help differentiate survival advantages between treatment modalities. Patients’ goals of care, comorbidities, and age should be considered when deciding appropriate treatment recommendations. Level of Evidence NA Laryngoscope, 130:405–412, 2020

show abstract

Survival Trends in Patients with Tracheal Carcinoma from 1973 to 2011

Cited by 4 publications

References 0 publications

Clinical characteristics, surgical treatments, prognosis, and prognostic factors of primary tracheal cancer patients: 20-year data of the National Cancer Center, China

Clinical characteristics, surgical treatments, prognosis, and prognostic factors of primary tracheal cancer patients: 20-year data of the National Cancer Center, China

The Prognostic Value of ¹⁸F-Fluorodeoxyglucose PET/CT in the Initial Assessment of Primary Tracheal Malignant Tumor: A Retrospective Study

Epidemiology and treatment trends for primary tracheal squamous cell carcinoma

Contact Info

Product

Resources

About

Survival Trends in Patients with Tracheal Carcinoma from 1973 to 2011

Cited by 4 publications

References 0 publications

Clinical characteristics, surgical treatments, prognosis, and prognostic factors of primary tracheal cancer patients: 20-year data of the National Cancer Center, China

Clinical characteristics, surgical treatments, prognosis, and prognostic factors of primary tracheal cancer patients: 20-year data of the National Cancer Center, China

The Prognostic Value of 18F-Fluorodeoxyglucose PET/CT in the Initial Assessment of Primary Tracheal Malignant Tumor: A Retrospective Study

Epidemiology and treatment trends for primary tracheal squamous cell carcinoma

Contact Info

Product

Resources

About

The Prognostic Value of ¹⁸F-Fluorodeoxyglucose PET/CT in the Initial Assessment of Primary Tracheal Malignant Tumor: A Retrospective Study